Related Experiment Video
Updated: Mar 23, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
Masked Hypertension: How to Identify and When to Treat?
1Department of Clinical and Experimental Sciences, University of Brescia, c/o 2ª Medicina Spedali Civili di Brescia, Piazza Spedali Civili 1, 25100, Brescia, Italy. damiano.rizzoni@unibs.it.
Insights
Masked hypertension, where clinic blood pressure is normal but ambulatory blood pressure is high, increases cardiovascular risk. Current guidelines suggest considering lifestyle changes and medication for this condition.
Area of Science:
- Cardiology
- Nephrology
- Hypertension Research
Background:
- Masked hypertension affects 1 in 7-8 individuals with normal clinic blood pressure (BP) and one-third of chronic kidney disease patients with normal clinic BP.
- Patients with masked hypertension exhibit increased risks for target organ damage and cardiovascular events compared to those with normal BP in both settings.
- Exclusion of masked hypertension patients from clinical trials due to normal clinic BP has left treatment efficacy unaddressed.
Purpose of the Study:
- To highlight the increased cardiovascular risk associated with masked hypertension.
- To address the knowledge gap regarding the benefits of hypertension treatment in masked hypertension patients.
- To inform current management strategies for masked hypertension.
Main Methods:
- Observational analysis of prevalence and risk factors for masked hypertension.
- Review of existing literature on cardiovascular outcomes in masked hypertension.
- Evaluation of current European guidelines regarding masked hypertension management.
Main Results:
- Masked hypertension is associated with a two-fold increased risk of cardiovascular events.
- Elevated ambulatory BP in the presence of normal clinic BP signifies significant cardiovascular risk.
- Lack of interventional trial data for masked hypertension treatment efficacy.
Conclusions:
- Masked hypertension poses a significant, under-recognized cardiovascular risk.
- While awaiting interventional study results, current European guidelines recommend lifestyle modifications and pharmacotherapy for masked hypertension.
- Further research is crucial to establish evidence-based treatment protocols for masked hypertension.
Abstract:
Approximately one out of 7-8 individuals with normal blood pressure (BP) in the clinic or doctor's office and one third of patients with chronic kidney disease with normal clinic BP have elevated ambulatory BP (masked hypertension). Patients with masked hypertension have an increased risk for target organ damage and a two-fold increased risk for cardiovascular events compared to patients with normal clinic and ambulatory BP. Despite this elevated risk for adverse outcomes, patients with masked hypertension have been excluded from hypertension trials because of their normal clinic BP. It is still unknown whether the reduction in target organ damage and adverse cardiovascular outcomes associated with treatment of hypertension extends to patients with masked hypertension. Ongoing and planned interventional studies will provide an answer to this crucial question in a few years. At present, it seems reasonable to follow the suggestion of current European guidelines, that lifestyle measures and drug treatment should be considered in the presence of masked hypertension.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Hypertension I: Introduction
Angle Closure Glaucoma: Treatment
Hypertension V: Nursing Management
Hypertension and Regulation of Blood Pressure

